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POLYMERIC PRODRUG 
RELATED APPLICATIONS 
This Application claims the benefit of U.S. Provisional 
Patent Application No. 61/885,915, filed Oct. 2, 2013, the 
entire disclosure of which is hereby incorporated by refer-
ence. 
2 
encapsulated in polymers. Entrapment in a solid matrix 
protects the molecules from enviroumental effects, and 
controlled release can be achieved. Persistent challenges, 
however, include instability of encapsulated drugs, incom-
plete release, and initial burst. 
GOVERNMENT SUPPORT 
This invention was made with govermnent support under 
grant number DGE-0653710 awarded by National Science 
Foundation (NSF). The govermnent has certain rights in the 
invention. 
Therefore, since cells and tissues require exposure to 
bioactive agents at particular concentrations and doses for 
certain durations, limited release kinetics is a shortcoming of 
many drug delivery systems in regenerative medicine. Con-
10 sequently, some have attempted to develop drugs conjugated 
to polymers to extend release duration. Among others, water 
soluble polymers, such as poly( ethylene glycol), polylysine, 
polyglutamic acid, and N-(2-hydroxypropyl)methacrylam-
TECHNICAL FIELD 
The present invention generally relates to polymeric pro-
drugs. In particular, certain embodiments of the present 
invention relate to polymer compounds that degrade to 
release an active agent. 
15 ide (HPMA) have been used for this purpose. With these 
systems, drugs are attached as pendants linked to the poly-
meric backbone via ester, amide, and hydrazone bonds. 
Depending on the spacer molecule chosen, drug release can 
be prolonged until cleavage in a desired environment, such 
BACKGROUND 
20 as pH-sensitive release in a lysosome. Other applications 
include targeting to specific cells and prolonging circulation 
time by shielding the drug from degradative enzymes and 
preventing opsonization. The number of molecules (i.e., 
payload) that can be attached to the backbone, however, is 
The need to treat bone defects resulting from age-related 
degenerative disease, trauma, and reconstructive surgery 
continues to grow at a significant rate. An estimated 2.2 
million bone grafting procedures are performed annually 
worldwide at a cost of $2.5 billion. Considering the "gray-
ing" of the U.S. population, in which the percentage of 
persons 55 years and older is expected to nearly double over 
the next 30 years, tremendous societal impact is inevitable. 
Consequently, the market for orthopedic biomaterials will 
continue to expand. 
25 limited by the number of functional groups required for 
conjugation. 
Hence, there remains a need for degradable compositions 
and compounds for treating tissue wounds, including bone 
tissue wounds, that can release drugs at a wound site in a 
30 controlled manner. There also remains a need for such 
compositions and compounds whose payload is not limited 
by the number of functional groups present on a polymer 
backbone. 
35 
Autologous (i.e., autografts) and cadaveric (i.e., 
allografts) bone are the most cormnonly used grafting mate-
rials to treat bone defects. Each, however, has drawbacks 
related to morbidity associated with a second surgical pro-
cedure for autografts and the potential for disease transmis- 40 
sian with allografts. These observations have led to devel-
opment of synthetic materials and tissue engineering 
approaches for use in bone regeneration. Bone graft substi-
tutes have used materials of natural and synthetic origin. 
Ongoing developments focus on enhancing biological activ- 45 
ity, such as by incorporating stem cells (e.g., mesenchymal 
stem cells) and growth factors (e.g., bone morphogenetic 
protein (BMP) 2) into bone graft substitute materials. 
Synthetic biodegradable polymers are also used for drug 
delivery and to aid in tissue regeneration. Candidate mate- 50 
rials include polyanhydrides, polyamides, polycarbonates, 
and polyorthoesters. The majority of resorbable synthetic 
polymers utilized for drug delivery and tissue engineering 
belong to the polyester family, such as poly(glycolic acid), 
poly(lactic acid), and poly(lactic-co-glycolic acid) (PLGA). 55 
These materials are relatively biocompatible, can degrade by 
the hydrolytic cleavage of ester bonds, and have degradation 
and mechanical properties that can be tailored by changing 
monomer ratio. Their degradation products of glycolic and 
lactic acid are metabolically removed from the body by 60 
conversion to carbon dioxide and water in the Krebs cycle. 
Other common polyesters include poly( E-caprolactone ), 
polyvalerolactone, polydioxanone, and their blends and 
copolymers. 
Furthermore, although certain drugs are intended for 65 
systemic therapy, many are most effective if targeted to or 
placed within a specific site. To this end, drugs are routinely 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This surmnary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
s=ary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the feature 
(s) mentioned; likewise, those features can be applied to 
other embodiments of the presently-disclosed subject mat-
ter, whether listed in this surmnary or not. To avoid exces-
sive repetition, this surmnary does not list or suggest all 
possible combinations of such features. 
In some implementations of the presently-disclosed sub-
ject matter, a compound is provided that comprises an 
initiator and an active agent that is covalently bonded to the 
initiator through a ring-opening polymerization process, an 
atom-transfer radical polymerization process, a Michael 
addition reaction, or a ring-opening metathesis polymeriza-
tion process. In some implementations the initiator com-
prises one or more hydroxyl groups configured to react and 
bind to the active agent, and exemplary initiators can include 
methoxypoly(ethylene glycol) (mPEG). In some implemen-
tations the active agent includes a lactone group, and exem-
plary active agents include statins, such as simvastatin. In 
this regard, in some implementations the compounds include 
a molar ratio of the initiator to the active agent is about 1: 1 
to about 1:100. 
US 9,433,638 Bl 
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In some implementations the compounds are a polymer 
that includes a linear or a branched structure. In some 
instances the compounds can include a molecular weight of 
about 500 Da to about 80 kDa. Exemplary compounds can 
further comprise a targeting agent that is selective for a 
target substance. 
In some implementations the compound is a copolymer, 
and in specific embodiments the compound is a diblock 
copolymer. For instance, certain embodiments of the present 
compounds include the formula: 
OYc-
0 
wherein n is about 1 to about 44 and m is about 1 to about 
258. 
The presently-disclosed subject matter also provides 
methods for making a compound. In some implementations 
the methods for making a compound include providing an 
initiator, mixing an active agent with the initiator to form a 
mixture, adding a catalyst to the mixture, and then reacting 
the mixture via a ring-opening polymerization process to 
form a compound that includes the initiator and the active 
agent. In some implementations the catalyst is selected from 
a metallic catalyst, an enzymatic catalyst, an organic cata-
lyst, and combinations thereof. 
4 
FIG. 4 includes a graph showing the polydispersity (PDI) 
of mPEG-polysimvastatin copolymers that were synthesized 
at different temperatures as a function of time. 
FIG. 5 includes a graph showing a 1H-NMR analysis of 
a mPEG-polysimvastatin copolymer. 
FIG. 6 includes a graph showing fourier transform infra-
red (FTIR) spectra of (a) mPEG, (b) simvastatin, (c) a 
simvastatin and mPEG blend (1 00: 1 ), and (d) a purified 
mPEG-polysimvastatin copolymer. 
1° FIG. 7 includes a schematic diagram showing a hydrolytic 
degradation mechanism of a mPEG-poly(simvastatin) copo-
lymer that results in the release of simvastatin molecules. 
FIG. 8 includes a graph showing the change in absorbance 
15 of a degrading mPEG-simvastatin copolymer as a function 
of time in 1 M NaOH and in phosphate buffered saline 
(PBS). 
FIG. 9 includes images showing histological differences 
four weeks post-implantation in woven bone layers that 
20 were been treated with either no drug (blank) or with an 
embodiment of the present simvastatin-loaded compounds 
(loaded). 
FIG. 10 includes a graph showing the thickness of woven 
bone layers formed over calvarias that were treated with 
25 either no drug (blank) or with an embodiment of the present 
simvastatin-loaded compounds (loaded). 
FIG. 11 includes a graph showing the new bone area and 
percentage of new formed mature bone formed over calva-
rias that were treated with either no drug (blank) or with an 
30 
embodiment of the present simvastatin-loaded compounds 
(loaded). 
FIG. 12 includes a schematic diagram showing an anionic 
ring-opening polymerization reaction to form poly( ethylene 
35 glycol)-block-poly(simvastatin). 
Further still, the presently-disclosed subject matter pro-
vides methods for treating a wound in a subject with the 
presently-disclosed compounds. In some implementations, 
the methods for treating a wound comprise administering a 
composition to the wound of a subject, the composition 40 
including an initiator and an active agent that is covalently 
bonded to the initiator through a ring-opening polymeriza-
tion. In some implementations the wound is a bone wound, 
FIG. 13A includes a gel permeation chromatogram show-
ing the peaks of an embodied compound synthesized with 
triazabicyclodecene (TBD) as well as the peaks of the initial 
reactants simvastatin and 550 Da mPEG. 
FIG. 13B includes a gel permeation chromatogram show-
ing the peaks of an embodied compound synthesized with 
triazabicyclodecene (TBD) as well as the peaks of the initial 
reactants simvastatin and 2 kDa mPEG. 
a skin wound, or a combination thereof. Also, in some 
implementations the step of administering a composition 
includes contacting the wound with the composition. 
Additional features and advantages of the present inven-
tion will also become evident to those of ordinary skill in the 
FIG. 13C includes a gel permeation chromatogram show-
45 ing the peaks of an embodied compound synthesized with 
stannous octoate as well as the peaks of the initial reactants 
simvastatin and 5 kDa mPEG. 
art after a study of the description, figures, and non-limiting 
50 
examples in this document. 
DESCRIPTION OF THE DRAWINGS 
Illustrative aspects of embodiments of the present inven- 55 
tion will be described in detail with reference to the follow-
ing figures wherein: 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
FIG. 1 includes a schematic diagram showing a ring-
opening polymerization reaction between simvastatin and 
poly(ethylene glycol) methyl ether (mPEG) that yields a 
mPEG-poly(simvastatin) diblock. 
60 understanding, and no unnecessary limitations are to be 
understood therefrom. 
FIG. 2 includes a graph showing molecular weights of 
mPEG-polysimvastatin copolymers analyzed by gel perme-
ation chromatography (GPC). 
FIG. 3 includes a graph showing the molecular weights of 65 
mPEG-polysimvastatin copolymers that were synthesized at 
different temperatures as a function of time. 
The presently-disclosed subject matter includes com-
pounds that comprise polymeric prodrugs. More specifi-
cally, embodiments of the present compounds include an 
initiator and an active agent, wherein the active agent is 
covalently bonded to the initiator through a ring-opening 
polymerization process, an atom-transfer radical polymer-
US 9,433,638 Bl 
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ization process, a Michael addition reaction, a ring-opening 
metathesis polymerization process, or a combination 
thereof. 
The present inventors have conceived the present poly-
meric prodrugs to solve some of the long-felt problems 
associated with known polymeric drug compositions. 
Embodiments of the present compounds are formed via a 
ring-opening polymerization process to combine an initiator, 
an active agent, and, optionally, other substances. Embodi-
ments of the compounds can thus form biodegradable com-
positions that degrade to release active forms of the active 
agents. The present compounds therefore differ from current 
polymeric drug formulations, which typically consist of 
drugs that are mixed with a polymeric material, encapsu-
lated in a polymeric material, or are conjugated to a poly-
meric material via functional groups located along the 
polymer's backbone. Thus, while the present compounds are 
themselves comprised of active agents, currently known 
materials simply include a bioinert polymer that serves as an 
agent carrier. 
In this regard, the mechanisms of polymer degradation 
and drug release of the present compounds can be the same 
since the chemical structure of the compound is comprised 
of the polymeric prodrug. In other words, since the active 
agent is directly incorporated into the present compounds, 
degradation of the compounds releases the active agent into 
the surrounding environment. Furthermore, polymerization 
of the prodrug (e.g., simvastatin) eliminates certain limita-
tions on the number of prodrug molecules provided by the 
compounds relative to current polymer-prodrug systems. As 
a result, relatively increased concentrations of active agents 
can be provided in the present compounds, which can 
provide more efficient therapeutic effects and localized 
release of active agents. 
In certain embodiments the presently-disclosed subject 
matter includes novel compounds and methods for making 
the same that include a biodegradable poly( ethylene glycol 
methyl ether-block-simvastatin) copolymer. Within a physi-
ological environment, the copolymer can degrade by hydro-
lysis of ester bonds into the osteogenic biomolecules of 
simvastatin for therapeutic treatment. 
The terms "biodegradable," "degradable," or the like are 
used interchangeably herein to refer to compounds and 
compositions that degrade under physiological conditions 
and/or are metabolized or excreted with little to no adverse 
effects to a subject. In certain embodiments, the compounds 
are metabolized or excreted without permanent damage to 
the subject. Biodegradable compounds can be hydrolytically 
degradable, can require cellular and/or enzymatic action to 
fully degrade, or both. Biodegradable compounds also 
include compounds that are broken down within cells. 
Degradation may occur by hydrolysis, oxidation, enzymatic 
processes, phagocytosis, or other processes. Degradation 
rates for compounds can vary, and may be on the order of 
hours, days, weeks, months, or years, depending on the 
embodiment of the compound. In some embodiments the 
compounds and compositions include prodrugs that can 
degrade to form active agents. 
6 
some compounds that are biocompatible. In some embodi-
ments, a biocompatible compounds does not induce irre-
versible side effects, and in some embodiments a compound 
is biocompatible if it does not induce long term side effects. 
One test to determine biocompatibility is to measure 
whether cells die upon being exposed a composition in vitro. 
For instance, a biocompatible compound may cause less 
than about 30%, 20%, 10%, or 5% cell death. 
As stated above, embodiments of the present compounds 
10 can comprise an initiator and an active agent. The initiator 
is not particularly limited except that it must be a capable of 
forming a polymeric material with the active agent. In some 
embodiments the initiator is a monomer compound that can 
undergo a ring-opening polymerization process with the 
15 active agent. For instance, in some embodiments the initiator 
comprises one or more hydroxyl groups, and can be referred 
to herein as a hydroxylated monomer. In some embodiments 
it is preferable that the initiator have one group (e.g., 
hydroxyl group) that can initiate a ring-opening polymer-
20 ization process, such as methoxypoly(ethylene glycol) 
(mPEG). 
The type and size of the initiator can also be varied to tune 
the characteristics of the resulting compound. In some 
embodiments the initiator and/or the active agent has a 
25 hydrophobic character or a hydrophilic character. In a spe-
cific embodiments comprising a mPEG initiator, the initiator 
has a hydrophilic character. Thus, by tuning the relative 
concentration and/or size of the mPEG initiator, the resulting 
compound can be imparted with a relatively more hydro-
30 phobic or hydrophilic character. 
The hydrophilic and hydrophobic characteristics of a 
compound can be tuned to, among other things, adjust the 
degradation rates of a compound. As described herein, some 
embodiments of compounds degrade via hydrolysis. Thus, 
35 for such embodiments, the degradation of the compound can 
increase as the hydrophilic character of the compound 
increases. In other words, hydrophilic compounds that more 
easily attract and absorb water permit can permit a greater 
degree of hydrolysis relative to more hydrophobic com-
40 pounds that repel or at least to not permit water to contact the 
compound as easily. For instance, in some embodiments the 
relative concentration and/or molecular weight of a hydro-
philic mPEG initiator can be increased in a compound to 
increase the hydrophilicity and relative degradation rate of 
45 the compound via hydrolysis. 
The active agent to be used in embodiments of the 
presently-disclosed subject matter is also not particularly 
limited so long as it is capable of forming a polymeric 
material with the initiator. In this regard, the term "active 
50 agent" is used herein to refer to compounds or entities that 
alter, promote, speed, prolong, inhibit, activate, or otherwise 
affect biological or chemical events in a subject. Exemplary 
active agents include, but are not limited to, osteogenic 
agents, osteoinductive agents, and osteoconductive agents, 
55 anti-cancer agents, antibiotics, immunosuppressants, anti-
viral agents, inhibitors, anti-histamines, anti-parasite agents, 
anti-protozoal agents, anti-fungal agents, analgesics, anti-
inflammatory agents, anti-angiogenic factors, angiogenic 
factors, targeting agents, polypeptides, cells, polynucle-Additionally or alternatively, embodiments of the pres-
ently-disclosed compounds can be biocompatible. The term 
"biocompatible" as used herein describes a characteristic of 
compounds that do not typically induce undesirable or 
adverse side effects when administered in vivo. For 
example, biocompatible compounds may not induce side 
effects such as significant inflammation and/or acute rejec- 65 
tion. It will be recognized that "biocompatibility" is a 
relative term, and some side effects can be expected even for 
60 otides, viruses, and vaccines. In some embodiments, the 
bioactive agent is a drug and/or a small molecule, such as a 
statin. Similar to the initiator, the active agent can comprise 
one or more groups that are suitable for undergoing a 
ring-opening polymerization process with the initiator. 
In some embodiments the active agent and/or the initiator 
is selected to provide the compounds with one or more 
osteoconductive, osteoinductive, osteogenic, and osteointe-
US 9,433,638 Bl 
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grating properties. The term "osteoconductive" as used 
herein refers to the property of a compound or composition 
thereof to be receptive to the growth of new bone and 
stimulate bone tissue growth. The term "osteoinductive" as 
used herein refers to the property of a compound or com-
position thereof to promote bone growth in surrounding 
tissues by recruiting and differentiating mesenchymal stem 
cells into osteoblasts, which are cells that have the potential 
8 
to form bone. The term "osteogenesis" as used herein refers 
to the property of a compound or composition thereof that 
can permit osteoprogenitor cells to remain on the compound 
or composition so that they may further proliferate, differ-
entiate into characteristic bone cells, and adhere within the 
compound or composition. The term "osseointegration" as 
used herein refers to the property of a compound or com-
position thereof that can bind integratively to the surround-
ing bone tissue. 
pounds are a copolymer comprising any suitable orientation 
of the initiator and the active agent. The term "copolymer" 
as used herein refers to a polymer formed of two or more 
different types of monomer units. Furthermore, in some 
embodiments the copolymer is an amphipathic block copo-
lymer, wherein a "block" copolymer refers to a structure 
comprising one or more sub-combinations of constitutional 
or monomeric units. Thus, the term copolymer is inclusive 
of block copolymers. In some embodiments the copolymer 
10 is a diblock copolymer comprising two blocks. Exemplary 
diblock copolymers can include a block comprised of ini-
tiator monomers and a block comprised of active agent 
monomers. For example, in embodiments comprising an 
15 mPEG initiator and a simvastatin active agent, the com-
pounds can include the following formula: 
Exemplary groups include lactone groups. One active 
agent that can include lactone groups is simvastatin. Simv-
astatin is compound that can be used to reduce cholesterol 20 
and that also can possess osteogenic, anti-inflammatory, 
angiogenic, and other properties. In some implementations 
of the present compounds, simvastatin is administered as a 
prodrug in lactone form, and can then undergo hydrolysis by 
endogenous esterases to generate a hydroxyacid that acts as 
a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor. By suppressing synthesis of mevalonate, 
farnesyl pyrophosphate, and geranylgeranyl pyrophosphate 
in a subject, simvastatin can be used to treat various diseases 
and conditions. For example, simvastatin can promote bone 30 
formation with increased bone morphogenic protein-2 
(BMP-2) expression. It can also inhibit formation and activ-
ity of osteoclasts. 
Further still, in some embodiments the compounds can act 
0 OYc 
0 
wherein n is about 1 to about 44, and m is about 1 to about 
248. The compounds are not limited to diblock copolymers, 
and can include alternating copolymers and the like. 
By virtue of directly binding the active agent to the 
initiator, the present compounds can form prodrugs of an 
active agent. The term "prodrug" is used herein to refer to an 
inactive or relatively less active form of an active agent that 
becomes active through one or more metabolic processes in 
a subject. For example, the present compounds can be 
administered to a subject as a prodrug that includes an 
initiator bound to an active agent, and, by virtue of being 
as and/or further comprise a targeting agent. The term 35 
"targeting agent" refers to a substance that can specifically 
bind another substance. In some embodiments a targeting 
agent specifically binds to particular proteins. Thus, target-
ing agents can include agents that specifically bind sub-
stances found at a wound site or on tissue to be treated. 
Embodiments of the present compounds can comprise any 
molecular weight, and those of ordinary skill will appreciate 
that the size of the compounds can be modified depending on 
the subject to be treated, the wound to be treated, the desired 
compound properties, and the like. In some preferred 45 
embodiments the compounds include a linear or branched 
structure with a molecular weight of about 500 Da, 1,000 
Da, 2,000 Da, 3,000 Da, 4,000 Da, 5,000 Da, 6,000 Da, 
7,000 Da, 8,000 Da, 9,000 Da, or 10 kDa. Still further, in 
some embodiments the compounds can comprise a linear or 50 
branched structure with a molecular weight of about 15 kDa, 
40 degraded by a metabolic process, the active agent is released 
from the compound in its active form. In some instances 
hydrolytic degradation of the present compounds converts 
the prodrug compounds from an inactive or relatively inac-
20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa, 
55 kDa, 60 kDa, 65 kDa, 70 kDa, 75 kDa, 80 kDa, 85 kDa, 
90 kDa, 95 kDa, or 100 kDa. 
Furthermore, embodiments of the compounds can have 55 
any suitable molar ratio of initiator to the active agent. The 
molar ratio can be adjusted depending on the desired prop-
erties of the compound (e.g., hydrophilic vs. hydrophobic), 
the amount of active agent to be delivered, and the like. 
Exemplary compounds can have a molar ratio of active 60 
agent (e.g., simvastatin) to initiator (e.g., mPEG) of about 
1:1 to about 100:1, including about 10:1, 20:1, 30:1, 40:1, 
50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. 
The present compounds can form polymers having vari-
ous configurations. In some embodiments the polymers are 65 
branched. In other embodiments the polymers are 
unbranched. Furthermore, in some embodiments the com-
tive form to an active form. In specific embodiments hydro-
lytic degradation releases biologically active simvastatin 
from a relatively inactive or less active mPEG-simvastatin 
copolymer. 
The presently-disclosed subject matter also includes phar-
maceutical compositions compnsmg the compounds 
described herein as well as a pharmaceutically acceptable 
carrier. The term "pharmaceutically acceptable carrier" 
refers to sterile aqueous or nonaqueous solutions, disper-
sions, suspensions or emulsions, as well as sterile powders 
for reconstitution into sterile solutions or dispersions just 
prior to use. The compositions can thus be in the form of a 
cream, paste, lotion, liquid, or the like. 
Proper fluidity can be maintained, for example, by the use 
of coating materials such as lecithin, by the maintenance of 
the required particle size in the case of dispersions, and by 
the use of surfactants. These compositions can also contain 
adjuvants such as preservatives, wetting agents, emulsifying 
agents and dispersing agents. It can also be desirable to 
include isotonic agents such as sugars, sodium chloride and 
the like. The compositions can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo-
rating sterilizing agents in the form of sterile solid compo-
sitions which can be dissolved or dispersed in sterile water 
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or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile solutions that can contain antioxidants, buffers, bac-
teriostats, bactericidal antibiotics, and solutes that render the 
compositions isotonic with the bodily fluids of the intended 
recipient; and aqueous and non-aqueous sterile suspensions, 
which can include suspending agents and thickening agents. 
The compositions can take such forms as suspensions, 
solutions, or emulsions in oily or aqueous vehicles, and can 10 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the compositions 
can be in powder form for constitution with a suitable 
vehicle, e.g., sterile pyrogen-free water, before use. 
The compositions can be presented in unit-dose or multi- 15 
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) 
condition requiring only the addition of sterile liquid carrier 
immediately prior to use. 
The presently-disclosed subject matter further includes 20 
methods for making a compound. In some embodiments the 
methods comprise providing an initiator, mixing an active 
agent with the initiator to form a mixture, adding a catalyst 
to the mixture, and reacting the mixture to form a compound 
that includes the initiator and the active agent. The step of 25 
reacting the mixture to form the compound can comprise 
reacting the mixture via a ring-opening polymerization 
process. 
With respect to the catalyst, various known catalysts may 
10 
The terms "treatment" or "treating" refer to the medical 
management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or 
disorder. This term includes active treatment, that is, treat-
ment directed specifically toward the improvement of a 
disease, pathological condition, or disorder, and also 
includes causal treatment, that is, treatment directed toward 
removal of the cause of the associated disease, pathological 
condition, or disorder. In addition, this term includes pal-
liative treatment, that is, treatment designed for the relief of 
symptoms rather than the curing of the disease, pathological 
condition, or disorder; preventative treatment, that is, treat-
ment directed to minimizing or partially or completely 
inhibiting the development of the associated disease, patho-
logical condition, or disorder; and supportive treatment, that 
is, treatment employed to supplement another specific 
therapy directed toward the improvement of the associated 
disease, pathological condition, or disorder. In some 
embodiments the term treatment refers to wound healing, 
tissue regeneration, or the like. 
Also, the term "subject" is inclusive of both human and 
animal subjects. Thus, veterinary uses are provided in accor-
dance with the presently disclosed subject matter and the 
presently-disclosed subject matter provides methods for 
preventing oxidative damage in mammals such as humans, 
as well as those mammals of importance due to being 
endangered, such as Siberian tigers; of economic impor-
tance, such as animals raised on farms for consumption by 
humans; and/or animals of social importance to humans, 
30 such as animals kept as pets or in zoos. Examples of such 
animals include but are not limited to: carnivores such as 
be utilized. Such catalysts include, but are not limited to, 
metallic catalysts, such as stannous octoate, aluminum iso-
propoxide, and yttrium isopropoxide, enzymatic catalysts, 
such as porcine pancreatic and Candida Antarctica lipases, 
and organic systems (organic catalysts), such as triazabicy-
clodecene and carboxylic acids with an alcohol. In some 35 
embodiments the mixture is provided with about 0.5 to 5 wt 
% of catalyst. In some embodiments the mixture for pre-
paring the compositions includes about 0.1 to 5 wt% of the 
catalyst. 
The reaction conditions as well as the reaction duration 40 
can be modified to tune the properties of the resulting 
compound. In some embodiments the step of reacting the 
mixture is performed at a predetermined temperature. The 
predetermined temperature can be, but is not limited to, 
temperatures of about 20° C., 30° C., 40° C., 50° C., 60° C., 45 
70° C., 80° C., 90° C., 100° C., 110° C., 120° C., 130° C., 
140° C., 150° C., 160° C., 170° C., 180° C., 190° C., 200° 
cats and dogs; swine, including pigs, hogs, and wild boars; 
ruminants and/or ungulates such as cattle, oxen, sheep, 
giraffes, deer, goats, bison, and camels; and horses. Also 
provided is the treatment of birds, including the treatment of 
those kinds of birds that are endangered and/or kept in zoos, 
as well as fowl, and more particularly domesticated fowl, 
i.e., poultry, such as turkeys, chickens, ducks, geese, guinea 
fowl, and the like, as they are also of economic importance 
to humans. Thus, also provided is the treatment of livestock, 
including, but not limited to, domesticated swine, ruminants, 
ungulates, horses (including race horses), poultry, and the 
like. 
In some embodiments of the present treatment methods, 
the step of administering the composition includes contact-
ing the composition with the any surface that can support the 
composition. In some embodiments the surface includes a 
tissue wound surface. The term "tissue" is used herein to 
refer to a population of cells, generally consisting of cells of 
C., 210° C., 220° C., 230° C., 240° C., 250° C., or any 
temperatures therebetween. In some implementations, the 
molecular weight of the resulting compound increases as the 
reaction temperature increases. 
Similarly, the reaction can be allowed to proceed for a 
predetermined time period. The time period can be about 1 
to about 25 hours, including about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
50 the same kind that perform the same or similar functions. In 
some embodiments tissue is part of a living organism, and in 
some embodiments tissue is tissue excised from a living 
organism or artificial tissue. In some embodiments tissue can 
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 55 
hours. In some embodiments the polydispersity and/or the 
molecular weight of the resulting compounds increase as the 
reaction time is increased. 
be part of skin, bone, an organ, or the like. 
Furthermore, the term "wound" is used herein to refer to 
any disease, condition, injury, defect, disorder, or the like 
present on any tissue that is in need of treatment. The wound 
itself can be a bone wound, a skin wound, some other tissue 
wound, or a combination thereof. In some embodiments a 
60 wound is bone (tissue) fracture. Thus, the presently-dis-
closed compounds can be administered to treat bone frac-
tures that are the result of an injury, disease, disorder, or the 
like. 
Further still, the presently-disclosed subject matter 
includes methods for treating a wound in a subject. In some 
embodiments the method comprises administering a com-
position to the wound, the composition including a com-
pound that comprises an initiator and an active agent that is 
covalently bonded to the initiator through a ring-opening 
polymerization process. The various methods of treatment 65 
that are described herein can utilize any of the compounds 
that are described in this paper. 
The composition can be administered with the compound 
in a prodrug form. Accordingly, as the composition that 
comprises the compounds degrades (e.g., via hydrolysis) 
within a subject, the active agent contained in the compound 
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is released into the surrounding environment in its active 
form. The delivery of active agent that results from the 
degradation of a composition can be beneficial when treating 
a localized wound on a subject. Degradation of the compo-
sition can also provide a sustained and controllable release 
of active agent at a wound site. 
12 
and then at 150° C. for 1 hour in a sand bath. After adding 
stannous octoate catalyst, reactions were allowed to proceed 
at different temperatures and for different times, with the 
reaction vessel continuously purged with nitrogen gas. The 
reaction product was precipitated in methylene chloride and 
diethyl ether followed by vacuum filtration. Molecular 
weights of the resulting polymers were analyzed by gel 
permeation chromatography (GPC) (FIG. 2). A distinct 
leftward shift can be seen as simvastatin "monomers" were 
Furthermore, the composition may be administered in 
several different forms. In some embodiments the compo-
sition is administered as a film. The film can be contacted 
with a wound on a subject. In other embodiments the 
composition is administered as nano- or microparticles, an 
oil-in-water emulsion, or as a three-dimensional scaffold. 
The scaffold itself can be porous or non-porous. Accord-
ingly, the step of administering the composition, depending 
10 consumed in the ROP reaction. FIGS. 3 and 4 shows 
on the type of composition, the wound to be treated, and the 15 
like, can including injecting the composition on to a wound, 
contacting the composition on to a wound site, applying the 
composition as a paste or liquid on to a wound, or the like. 
The present compositions and compounds can also be 
used as coating materials to coat medical devices, implants, 20 
or other devices configured to be implanted in or on a 
subject. The device can therefore include medical devices, 
biomaterials, or both. Devices that have been coated with the 
present compounds and compositions can provide a sus-
tained and controlled delivery of active agent. The release of 25 
active agent from a coating can help ameliorate or accelerate 
the treatment of an existing wound. The release of active 
agent from a coating can also help mitigate adverse effects 
that may be caused by the implanted device. 
quantification of the molecular weight and polydispersity of 
the polymers as a function of reaction temperature at 24 
hours. In these procedures, polymers reaching nearly 80 kDa 
were synthesized. 
Copolymer molecular weight, composition, and polydis-
persity were characterized by GPC, by preparing 5 to 10 
mg/ml samples in tetrahydrofuran. Select samples were 
prepared in deuterated chloroform for supplementary struc-
tural analysis by 1H-NMR (University of Kentucky NMR 
Facility; Lexington, Ky.) (FIG. 5). Fourier transform infra-
red (FTIR) spectroscopy was also be used to evaluate the 
ratio of functional groups unique to individual block com-
ponents of the copolymer and carbonyl peak shift analysis 
(FIG. 6). 
Degradation kinetics with associated measurement of 
released simvastatin-containing molecules were assessed for 
films cast from the synthesized copolymers. Following 
incubation in a physiological buffer for increasing periods, 
mass loss was quantified. FIG. 7 shows a schematic of the 
EXAMPLES 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
presently-disclosed subject matter. Furthermore, some of the 
examples described herein may be prophetic examples. 
30 hypothesized degradation mechanism. Degradation studies 
were conducted at both physiological (neutral) and alkaline 
(up to pH 12) conditions. Over a six week period, slow 
polymer degradation with associated slow release of simv-
astatin was observed (FIG. 8). For 16-18 mg samples, the 
35 cumulative drug amounts released were 108 and 266 flg in 
neutral (phosphate-buffered saline, PBS) and alkaline 
(NaOH) solutions, respectively. After an initial burst of 59 
flg in 24 hr, a zero-order release rate was observed in NaOH 
with a constant of 7.4 flg·hr- 1 between 1 and 10 days. A 
Example 1 
This Example describes a process for making exemplary 
compounds comprising mPEG and a simvastatin active 
agent. This Example also describes procedures conducted to 
characterize the synthesized copolymers. 
40 first-order release rate followed with a constant of 21 d- 1 for 
the remainder of the degradation period. In PBS, after an 
initial burst of37 flg in 24 hr, 2.5 flg was released during the 
following 8 days. A zero-order release constant of 2.1 flg·d- 1 
was determined for the remainder of the degradation period. 
45 These degradation/release rates would yield formulations 
that can deliver the active agent for periods exceeding one 
Stam1ous octoate was used for lactone polymerization 
given its relatively low cost, low toxicity, and high effi-
ciency. With this reaction, the metal catalyst first forms a 
complex with the hydroxyl group of the initiator (i.e., 50 
mPEG) to form an alkoxide. The more reactive alkoxide 
then begins chain propagation by coordinating with the 
lactone ring of the monomer, followed by insertion of the 
ring into the alkoxide's metal-oxygen bond. Throughout the 
process, the alkoxide acts as a nucleophile by attacking the 55 
carbon of the ring's carbonyl group leading to cleavage of 
the acyl bond and extended chain formation. FIG. 1 shows 
a simplified representation of the exemplary simvastatin 
ROP reaction. 
year. 
Example 2 
This Example describes procedures to evaluate the effi-
cacy of simvastatin-containing materials for treating bone 
wounds. 
Simvastatin-based films are studied in a supracalvarial 
implantation model to assess osteogenic effects of simvas-
tatin released from an erodible polymer system. This model 
enables testing of a material's ability to enhance formation 
of bone from existing bone surfaces outward (i.e., apposi-
tional bone formation). For this purpose, blank (no drug) and 
simvastatin-releasing implants were placed on the exposed 
calvarium, from which the periosteum containing osteopro-
genitor cells had been displaced. 
Methoxypoly( ethylene glycol) (mPEG) served as initiator 60 
in the ring-opening polymerization (ROP) reactions. Advan-
tages of mPEG include that it comprises a single hydroxyl 
functionality and a boiling point suitable for the higher 
temperature reactions that can obtain higher molecular 
weight polymer. 
Intimately opposed to the pre-existing lamellar bone of 
the calvarium was a layer of newly formed woven bone. The 
65 thickness of this layer depended on type of device. In the 
blank (no-drug control) animals, a low level of bone activity 
was observed, whereas simvastatin-loaded release devices 
The initial synthesis began with heating a 1:100 molar 
ratio of 5 kDa mPEG to simvastatin at 120° C. for 2 hours 
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stimulated formation of much more woven bone over the 
mature, lamellar calvarial bone (FIG. 9). Quantitatively, 
whereas disturbing the periosteum stimulated an average of 
100 f.Ull of woven bone formation, controlled release 
enhanced bone formation by over 110% (p<0.05) (FIG. 10). 
FIG. 11 shows the total area of new bone and the percentage 
of mature matrix relative to total bone. Simvastatin-loaded 
implants elicited 163% larger new bone area compared to 
controls, and the percentage of mature bone matrix (26%) 
was also higher than that of the controls (21%) (p<0.05). 10 
Example 3 
This Example describes another exemplary process for 
15 
synthesizing an embodiment of the present compounds 
using triazabicyclodecene (TBD) as a catalyst. Unless stated 
otherwise, the same synthesis procedure described in 
Example 1 was followed. 
Triazabicyclodecene was selected was selected as the 20 
organic system to be used as a catalyst because of its efficient 
performance at ambient temperatures, ability to work with-
out the need of a co-catalyst, and accessibility. The ring-
opening polymerization mechanism ofTBD is anionic (FIG. 
12). Without being bound by theory, the amidine imine 25 
nitrogen of the nucleophilic catalyst attacks the carbonyl 
group on the lactone ring of simvastatin to form a temporary 
intermediate as the acyl bond is broken. The secondary 
amine within the catalyst activates or becomes attracted to 
the alcohols within the reaction mixture (i.e., both on mPEG 30 
and the propagating polysimvastatin block) to form the 
mPEG-poly(simvastatin) diblock copolymer through hydro-
gen bonding. 
The results showed that TBD was able to form poly 
(ethylene glycol)-block-poly(simvastatin) with efficiency in 35 
polymerization using 550 Da and 2 kDa mPEG. A leftward 
shift of the polymer peak or shoulder is seen relative to the 
mPEG peaks, indicating an increase in overall molecular 
weight of the chains, and hence, growth of the poly(simv-
astatin) block (FIGS. 13A to 13C). Table 1 summarizes 40 
molecular weight and polydispersity results for the compo-
nents and copolymers synthesized. 
TABLE 1 
MW comparisons of the diblock copolymers using 550 Da, 
2 kDa and 5 kDa mPEG measured via GPC. 
%of crude 
Sample Mn (Da) Mw(Da) MJMn product 
simvastatin 300 320 1.0 
550 Da mPEG 470 560 1.2 
2 kDa mPEG 3200 3400 1.1 
5 kDa mPEG 8300 8800* 1.1 
550 Da mPEG- 6500 10400 1.6 21 
poly(simvastatin) 
100:2 via TBD 
2kkDa mPEG- 12700 15200 1.2 9.2 
poly(simvastatin) 
100:2 via TBD 
5 kDa mPEG- 13100 29500 2.3 62 
poly(simvastatin) 
100:1 via 
stannous 
*The GPC molecular weight of mPEG registered higher than the expected value because 
its chemistry differs from the polystyrene standards used for calibration. 
45 
50 
55 
60 
14 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although many 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a prodrug" includes a plurality of such prodrug, and 
so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about." Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions in some embodiments of ±20%, in some embodiments 
of ±10%, in some embodiments of ±5%, in some embodi-
ments of ±1 %, in some embodiments of ±0.5%, and in some 
embodiments of ±0.1% from the specified amount, as such 
variations are appropriate to perform the disclosed method. 
It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
Throughout this application, various publications are ref-
erenced. All such references, including the follow listed 
references, are incorporated herein by reference. 
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What is claimed is: 
1. The compound having the formula: 
0 
wherein: 
n is about 1 to about 44; and 
m is about 1 to about 258. 
OYc 
0 
. 2. The compound of claim 1, further comprising a target-
mg agent. 85. Muthu M S, Nanoparticles based on PLGA and its 
co-polymer: An overview, Asian Journal of Pharmaceu-
tics 2009. 
86. Athanasiou K A, Niederauer G G, Agrawal C M, 
Sterilization, Toxicity, Biocompatibility and Clinical 
Applications of Polylactide acid/Polyglycolic acid copo-
lymers, Biomaterials, (17)1996, 93-102. 
3. The compound of claim 1, wherein the compound 
30 includes a linear or branched structure with a molecular 
weight of about 500 Da to about 80 kDa. 
4. The compound of claim 1, wherein a molar ratio of the 
initiator to the active agent is about 1:1 to about 1:100. 
87. Kalyanasundaram K and Thomas J K, Environmental 
Effects on \'ibronic Band Intensities in Pyrene Monomer 
Fluorescence and Their Application in Studies of Micellar 
Systems, Journal of the American Chemical Society, 
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5. A method for making the compound of claim 1, 
35 comprising: 
88. Mikos A Get a!. Mechanical Properties of a Biodegrad- 40 
able Bone Regeneration Scaffold, Journal ofBiomechani-
cal Engineering (122) 2000, 286-287. 
89. Azevedo H Sand Reis R L, Biodegradable Systems in 
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Press LLC, 2005, 177-349. 
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Orthod Craniofacial (8) 2005, 162-173. 
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providing methoxypoly(ethylene glycol); 
mixing imvastatin with the methoxypoly(ethylene glycol) 
to form a mixture; 
adding a catalyst to the mixture; and 
reacting the mixture via a ring-opening polymerization 
process to form the compound of claim 1. 
6. The method of claim 5, wherein a molar ratio of the 
methoxypoly( ethylene glycol) to simvastatin is about 1:1 to 
about 1:100. 
7. The method of claim 5, wherein the catalyst is selected 
from a metallic catalyst, an enzymatic catalyst, an organic 
catalyst, and combinations thereof. 
8. A method for treating a wound in a subject, comprising: 
administering the composition of claim 1 to the wound. 
9. The method of claim 8, wherein the step of adminis-
tering a composition includes contacting the wound with the 
composition. 
10. The method of claim 8, wherein the wound is a bone 
wound, a skin wound, or a combination thereof. 
* * * * * 
